ZA968334B - Compounds compositions and methods for inhibiting the binding of proteins containing an sh2 domain to cognate phosphorylated proteins - Google Patents

Compounds compositions and methods for inhibiting the binding of proteins containing an sh2 domain to cognate phosphorylated proteins

Info

Publication number
ZA968334B
ZA968334B ZA968334A ZA968334A ZA968334B ZA 968334 B ZA968334 B ZA 968334B ZA 968334 A ZA968334 A ZA 968334A ZA 968334 A ZA968334 A ZA 968334A ZA 968334 B ZA968334 B ZA 968334B
Authority
ZA
South Africa
Prior art keywords
proteins
inhibiting
domain
binding
methods
Prior art date
Application number
ZA968334A
Inventor
Elizabeth A Lunney
Mark Stephen Plummer
Alan Robert Saltiel
Aurash Shahripour
Charles John Stankovic
Kimberley Suzanne Para
Josyula Venkata Nagendr Prasad
Tomi Sawyer
Juswinder Singh
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ZA968334B publication Critical patent/ZA968334B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3834—Aromatic acids (P-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3882—Arylalkanephosphonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4056—Esters of arylalkanephosphonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4075—Esters with hydroxyalkyl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA968334A 1995-10-04 1996-10-03 Compounds compositions and methods for inhibiting the binding of proteins containing an sh2 domain to cognate phosphorylated proteins ZA968334B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US495495P 1995-10-04 1995-10-04

Publications (1)

Publication Number Publication Date
ZA968334B true ZA968334B (en) 1997-05-13

Family

ID=21713373

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA968334A ZA968334B (en) 1995-10-04 1996-10-03 Compounds compositions and methods for inhibiting the binding of proteins containing an sh2 domain to cognate phosphorylated proteins

Country Status (3)

Country Link
AU (1) AU7392696A (en)
WO (1) WO1997012903A1 (en)
ZA (1) ZA968334B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207397B1 (en) 1996-04-18 2001-03-27 Ariad Pharmaceuticals, Inc. In vitro fluorescence polarization assay
EP1030853A1 (en) * 1997-11-12 2000-08-30 Ariad Pharmaceuticals, Inc. Novel signal transduction inhibitors, compositions containing them
US6156784A (en) * 1997-12-18 2000-12-05 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as phosphotyrosine mimics
EP1045836B1 (en) * 1997-12-18 2008-03-05 Boehringer Ingelheim Pharmaceuticals Inc. Pyridones as src family sh2 domain inhibitors
US6770461B1 (en) 1998-10-23 2004-08-03 Genome Therapeutics Corporation High bone mass gene of 11q13.3
US6780609B1 (en) 1998-10-23 2004-08-24 Genome Therapeutics Corporation High bone mass gene of 1.1q13.3
JP2002506873A (en) * 1998-03-18 2002-03-05 アリアド・ファーマシューティカルズ・インコーポレイテッド Heterocyclic signaling inhibitors and compositions containing them
CA2345459A1 (en) 1998-11-12 2000-05-18 Regine Bohacek Bicyclic signal transduction inhibitors, compositions containing them & uses thereof
AU770920C (en) 1999-03-23 2004-10-07 Georgetown University Phenylalanine derivatives
FR2793796A1 (en) * 1999-04-14 2000-11-24 Hoechst Marion Roussel Inc Imidazole derivatives having Src SH2 receptor antagonist activity for the prevention and treatment of osteoporosis, auto-immune diseases, proliferative diseases, cancers, allergies and other disorders
FR2796381A1 (en) * 1999-07-12 2001-01-19 Hoechst Marion Roussel Inc Thiazepin and caprolactam bicyclic derivatives, useful in the treatment of e.g. osteoporosis and other bone disorders, infections, allergies or cancers
AU5626900A (en) * 2000-04-05 2001-10-23 Genome Therapeutics Corp The high bone mass gene of 11q13.3
US7425537B2 (en) 2000-08-22 2008-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SH2 domain binding inhibitors
CA2419870A1 (en) * 2000-08-22 2002-02-28 Yang Gao Sh2 domain binding inhibitors
US7514594B2 (en) 2001-05-11 2009-04-07 Wyeth Transgenic animal model of bone mass modulation
US7416849B2 (en) 2001-05-11 2008-08-26 Oscient Pharmaceuticals Corporation HBM variants that modulate bone mass and lipid levels
US20040038860A1 (en) 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions
US7098241B2 (en) 2002-12-16 2006-08-29 Hoffmann-La Roche Inc. Thiophene hydroxamic acid derivatives
US7282339B2 (en) * 2003-09-17 2007-10-16 Invitrogen Corporation Competitive immunoassay
WO2011133348A1 (en) * 2010-04-21 2011-10-27 Pharmacofore, Inc. Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof
EP2994143A4 (en) 2013-05-08 2017-02-01 Board of Regents, The University of Texas System Stat6 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU606808B2 (en) * 1988-06-29 1991-02-14 Otsuka Pharmaceutical Factory, Inc. Arylcarboxamide substituted by alkylphosphonates, process for preparing the same and a pharmaceutical composition containing the same
WO1991015495A1 (en) * 1990-04-02 1991-10-17 Pfizer Inc. Benzylphosphonic acid tyrosine kinase inhibitors

Also Published As

Publication number Publication date
WO1997012903A1 (en) 1997-04-10
AU7392696A (en) 1997-04-28

Similar Documents

Publication Publication Date Title
ZA968334B (en) Compounds compositions and methods for inhibiting the binding of proteins containing an sh2 domain to cognate phosphorylated proteins
EP0871444A4 (en) 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
AU4915796A (en) Inhibitors of prenyl transferases
PL324819A1 (en) Derivatives of 4-mercaptopyrrolidine as inhibitors of farnesil transferase
EP0859771A4 (en) Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
AU7482396A (en) Substituted aryl pyrroles, compositions containing such compounds and methods of use
PL323736A1 (en) Composition maintaining release of non-aggregable erythropoietin
IL116957A0 (en) Substituted heterocyclic compounds their preparation and pharmaceutical compositions containing them
IL117294A (en) Organosilicon compounds and compositions containing them
PL336990A1 (en) 3(5)-heteroaryl group substituted pyrazoles as inhibitors of kinase p 38
AU2371095A (en) Compositions and methods for inhibiting the binding of e-selectin or p-selectin to sialyl-lewisx or sialyl-lewisa
AU2872795A (en) Inhibition of platelet binding
AU5211796A (en) Biocidal compositions comprising mixtures of halopropynyl compounds and sulfur containing triazines
AU6485996A (en) Methods and compositions for modulation and inhibition of teomerase
IL123095A0 (en) Pharmaceutical compositions containing fluconazole for inhibiting the growth of cancers
AU7529096A (en) Substituted aryl pyrroles, compositions containing such compounds and methods of use
AU1075099A (en) Method for inhibiting the binding of low density lipoprotein to blood vessel matrix
IL123094A0 (en) Pharmaceutical compositions containing griseofulvin for inhibiting the growth of cancers
PL319163A1 (en) Inhibitors of 5 alpha-reductase
IL129177A0 (en) Methods and compositions for lipidization of hydrophilic molecules
GB9507297D0 (en) New composition of matter
EP0835104A4 (en) Use of stat 5 sh2 domain specific compounds to enhance erythropoiesis
AU7377298A (en) Methods and compositions for use of (iso)eugenol methyltransferase
GB9509844D0 (en) Screening for inhibitors of TCR-MHC interactions
AU2556195A (en) CD40 binding compositions and methods of using same